Table 4.
Clinical pulmonary infection score and procalcitonin level during the study.*
| Result | PCT group (n = 24) |
Conventional group (n = 26) |
p value |
|---|---|---|---|
| CPIS day 0 | 7.4 ± 0.9 | 7.2 ± 1.2 | 0.38 |
| CPIS NF-GNB day 0 | 7.3 ± 0.8 | 7.2 ± 1.2 | 0.81 |
| CPIS day 8 | 3.6 ± 0.7 | 3.7 ± 0.8 | 0.18 |
| CPIS NF-GNB day 8 | 3.6 ± 1 | 3.7 ± 0.8 | 0.77 |
| PCT day 8, median (interquartile range), ng/ml |
0.24 (0.11– 0.4) | 0.2 (0.09–0.6) | 0.82 |
| PCT NF-GNB day 8, median (interquartile range), ng/ml |
0.3 (0.2–0.4) | 0.17 (0.11–0.35) | 0.2 |
| PCT day 8 < 0.5 ng/ml | 19 (79.2%) | 19 (73.1%) | 0.61 |
| PCT NF-GNB day 8 < 0.5 | 15/19 (78.9%) | 14/19 (73.7%) | 0.8 |
| PCT day 10, ng/ml | 0.44 ± 0.04 | – | |
| PCT day 10 < 0.5 ng/ml | 5/5 (100%) | – |
Day 0: the day of diagnosis of VAP; day 8: 7 days after appropriate treatment of VAP.
*
Data are presented as mean ± SD or n (%) unless otherwise indicated.
CPIS, Clinical Pulmonary Infection Score; CPIS NF-GNB, clinical pulmonary infection score of patients with VAP caused by nonfermentative gram-negative bacilli; PCT, serum procalcitonin level; PCT NF-GNB, serum procalcitonin level of patients with VAP caused by nonfermentative gram-negative bacilli; SD, standard deviation; VAP, ventilator-associated pneumonia.